Consensus NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Delayed Nasdaq Other stock markets 03:51:34 2024-04-19 pm EDT			5-day change	1st Jan Change
12.09 ^USD	+0.33%		-10.91%	-19.02%

Apr. 10	Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	MT
Apr. 05	NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer	MT

Evolution of the average Target Price on NovoCure Limited

Price target over the last 5 years

History of analyst recommendation changes

0111.4xciSyACNEnXSQeMjPCqPBl9EOj9MKZfe-QYYOwhI00.pnJ0DFBsfTnjG1-59rLiDV1FQYOzYucPHq8qUK4RZj6mXlUjWW5-DpYuZA~974db7981f05a63b2e72f99be89f2b53

Analyst Recommendations on NovoCure Limited

Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	Apr. 10	MT
Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating	Apr. 03	MT
Evercore ISI Adjusts Price Target on NovoCure to $15 From $14, Keeps In Line Rating	Feb. 23	MT
Wedbush Adjusts NovoCure Price Target to $21 From $23, Maintains Neutral Rating	23-10-26	MT
Wells Fargo Adjusts NovoCure's Price Target to $49 From $102, Keeps Overweight Rating	23-08-29	MT
Wedbush Cuts NovoCure's Price Target to $23 From $46 After Drug Failure in Clinical Study, Maintains Neutral Rating	23-08-28	MT
HC Wainwright Downgrades NovoCure to Neutral From Buy, Cuts Price Target to $25 From $85	23-08-28	MT
Piper Sandler Lowers Price Target on NovoCure to $35 From $45, Maintains Overweight Rating	23-08-28	MT
Wedbush Cuts NovoCure's Price Target to $23 From $46, Maintains Neutral Rating	23-08-28	MT
Piper Sandler Upgrades NovoCure to Overweight From Neutral, Price Target is $45	23-08-08	MT
SVB Securities Initiates NovoCure at Outperform With $51 Price Target	23-08-04	MT
Evercore ISI Upgrades NovoCure to In Line From Underperform, Price Target is $33	23-07-31	MT
Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	23-06-07	MT
Piper Sandler Adjusts Price Target on NovoCure to $62 From $67, Maintains Neutral Rating	23-06-07	MT
Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	23-06-07	MT
Wells Fargo Upgrades NovoCure to Overweight From Equalweight, Adjusts Price Target to $104 From $70	23-05-16	MT
Wedbush Cuts NovoCure's Price Target to $53 From $65 After Lower-Than-Expected Q1 Results, Keeps Underperform Rating	23-05-05	MT
JPMorgan Downgrades NovoCure to Underweight From Neutral, Adjusts Price Target to $50 From $99	23-03-17	MT
Piper Sandler Adjusts NovoCure's Price Target to $80 From $70, Maintains Neutral Rating	23-01-17	MT
JPMorgan Adjusts NovoCure's Price Target to $99 From $86, Keeps Neutral Rating	23-01-06	MT
Wells Fargo Downgrades NovoCure to Equalweight From Overweight, Adjusts Price Target to $107 From $89	23-01-06	MT
HC Wainwright Adjusts NovoCure's Price Target to $140 From $100, Maintains Buy Rating	23-01-05	MT
Wells Fargo Upgrades NovoCure to Overweight From Equalweight, Adjusts Price Target to $89 From $74	22-11-29	MT
Wells Fargo Adjusts Price Target on NovoCure to $74 From $70, Keeps Equal Weight Rating	22-10-28	MT
Truist Securities Trims NovoCure's Price Target to $102 From $105, Maintains Buy Rating	22-10-28	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

12.05 USD

Average target price

26.17 USD

Spread / Average Target

+117.15%

High Price Target

42 USD

Spread / Highest target

+248.55%

Low Price Target

15 USD

Spread / Lowest Target

+24.48%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NovoCure Limited

Piper Sandler
Wells Fargo Securities
Evercore ISI
Wedbush
HC Wainwright
SVB Securities LLC
JPMorgan Chase
Truist Securities
Loop Capital
Oppenheimer
Mizuho Securities
Northland Securities
J.P. Morgan Chase

Ratings for NovoCure Limited

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar